Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Exact Sciences reported a quarterly loss of $0.27 per share, better than the Zacks Consensus Estimate of a loss of$0.53, and improved from a loss of $0.72 per share a year ago, representing an earnings surprise of 49.06$646.89 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 2.36% and up from $553 million in the same quarter last year [1] - Exact Sciences has surpassed consensus EPS estimates and revenue estimates in each of the last four quarters [1] 分组2 - The stock has underperformed, losing about 15.2% since the beginning of the year compared to the S&P 500's gain of 4.3% [2] - The future performance of Exact Sciences' stock will depend on management's commentary during the earnings call and the company's earnings outlook [2] - Current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of$656.92 million, and for the current fiscal year, it is -$1.15 on revenues of$2.82 billion [4] 分组3 - The Medical - Biomedical and Genetics industry, to which Exact Sciences belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [4] - The Zacks Rank for Exact Sciences is 1 (Strong Buy), suggesting that the stock is expected to outperform the market in the near future [3]